drugset / Trial / NCT07145229

Safety and Efficacy of ABP-745 in Participants With an Acute Gout Flare

NCT07145229

Phase 2 Recruiting 380 enrolled Atom Therapeutics Co., Ltd
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, international multicenter, colchicine and placebo-controlled study to evaluate the efficacy and safety of ABP-745 in subjects with acute gout. Efficacy of ABP-745 in reducing pain and swelling compared with standard colchicine treatment and placebo will be evaluated in participants with acute gout. The primary efficacy measurement will be pain score after treatment.

Timeline

Start
2025-08-26
Primary completion
2026-05
Completion
2026-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ABP-745 Unknown Oral
Comparator Colchicine Small molecule Oral

Indications